Ovid Therapeutics (OVID) Q1 2024 Earnings
OVID·Reported May 14, 2024·Before market open
Ovid Therapeutics reported Q1 2024 revenue of $148.0K, beat analyst consensus of $60.0K by $88.0K. Diluted EPS came in at $-0.17, beat the $-0.23 consensus by $0.06.
Revenue
$148.0Kbeat by $88.0K
Consensus: $60.0KDiluted EPS
$-0.17beat by $0.06
Consensus: $-0.23
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Ovid Therapeutics's Q1 2024 earnings report.
Ovid Therapeutics (OVID) reported Q1 2024 earnings on May 14, 2024 before market open.
Ovid Therapeutics reported revenue of $148.0K and diluted EPS of $-0.17 for Q1 2024.
Revenue beat the consensus estimate of $60.0K by $88.0K. EPS beat the consensus estimate of $-0.23 by $0.06.
You can read the 10-Q periodic report (0001628280-24-023067) directly on SEC EDGAR. The filing index links above go to sec.gov.